Capricor Therapeutics Stock Jumps As HC Wainwright Boosts Price Target On DMD Drug Potential: Retail Buzz Grows

Shares of Capricor Therapeutics, Inc. (CAPR) surged over 8% on Friday morning after H.C. Wainwright raised its price target to $77 from $40, implying a 315% upside from current levels.

The brokerage maintained a ‘Buy’ rating, citing the potential of Capricor’s drug candidate, deramiocel, to treat Duchenne muscular dystrophy (DMD) cardiomyopathy.

H.C. Wainwright said it sees "exciting times with strong science and data foundation" for the biotech firm.

On Stocktwits, CAPR was among the top 10 trending tickers as of 8:50 a.m. ET, though retail sentiment shifted to ‘neutral’ from ‘bullish’ a day ago.

Despite this, many users praised the company’s progress, including CEO Linda Marban’s leadership.

The stock’s following has jumped nearly 10% in the past month, while message volume surged over 1,700% during the same period.

Earlier this week, Capricor initiated the rolling submission process with the U.S. FDA for a Biologics License Application (BLA) for deramiocel, aiming for full approval by year’s end.

The submission is backed by data from its Phase 2 HOPE-2 trials and natural history data from Vanderbilt University Medical Center and Cincinnati Children’s Hospital.

Capricor has already secured a commercialization deal for deramiocel with Nippon Shinyaku in Europe, which includes a $20 million upfront payment, up to $715 million in potential milestones, and a double-digit share of revenue.

Read next: Triumph Group, Symbotic, Cloudflare: 3 Stocks Retail Investors Are Most Bullish On Pre-Market Today